PT  - JOURNAL ARTICLE
AU  - Farhan Chaudhry
AU  - Helena Bulka
AU  - Anirudha S. Rathnam
AU  - Omar M Said
AU  - Jia Lin
AU  - Holly Lorigan
AU  - Eva Bernitsas
AU  - Jacob Rube
AU  - Steven J Korzeniewski
AU  - Anza B Memon
AU  - Phillip D. Levy
AU  - Adil Javed
AU  - Robert Lisak
AU  - Mirela Cerghet
TI  - COVID-19 in Multiple Sclerosis Patients and Risk Factors for Severe Infection
AID  - 10.1101/2020.05.27.20114827
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.05.27.20114827
4099  - http://medrxiv.org/content/early/2020/05/29/2020.05.27.20114827.short
4100  - http://medrxiv.org/content/early/2020/05/29/2020.05.27.20114827.full
AB  - Importance Multiple sclerosis patients have been considered a higher-risk population for COVID-19 due to the high prevalence of disability and disease-modifying therapy use; however, no study has identified clinical characteristics of multiple sclerosis associated with worse COVID-19 outcomes.Objective To evaluate the clinical characteristics of multiple sclerosis, including staging, degree of disability, and disease-modifying therapy use that are associated with worse outcomes from COVID-19.Design Prospective cohort study looking at the outcomes of multiple sclerosis patients with COVID-19 between March 1st and May 18th 2020.Setting This is a multicenter study of three distinct hospital systems within the U.S.Participants The study included 40 consecutive patients with nasopharyngeal/oropharyngeal PCR-confirmed COVID-19 infection.Exposures Multiple sclerosis staging, severe disability (based on baseline-extended disability status scale equal to or greater than 6.0) and disease-modifying therapy.Main Outcomes and Measure Severity of COVID-19 infection was based on hospital course, where a mild course was defined as the patient not requiring hospital admission, moderate severity was defined as the patient requiring hospital admission to the general floor only, and most severe was defined as requiring intensive care unit admission and/or death.Results For the 40 patients, the median age was 52(45.5-61) years, 16/40(40%) were male, and 21/40(52.5%) were African American. 19/40(47.5%) had mild courses, 15/40(37.5%) had moderate courses, and 6/40(15%) had severe courses. Patients with moderate and severe courses were significantly older than those with a mild course (57[50-63] years old and 66[58.8-69.5] years old vs 48[40-51.5] years old, P=0.0121, P=0.0373). There was differing prevalence of progressive multiple sclerosis staging in those with more severe courses (severe:2/6[33.3%]primary-progressing and 0/6[0%]secondary-progressing, moderate:1/14[7.14%] and 5/14[35.7%] vs mild:0/19[0%] and 1/19[5.26%], P=0.0075, 1 unknown). Significant disability was found in 1/19(5.26%) mild course-patients, but was in 9/15(60%, P=0.00435) of moderate course-patients and 2/6(33.3%, P=0.200) of severe course-patients. Disease-modifying therapy prevalence did not differ among courses (mild:17/19[89.5%], moderate:12/15[80%] and severe:3/6[50%], P=0.123).Conclusions and Relevance Multiple sclerosis patients with more severe COVID-19 courses tended to be older, were more likely to suffer from progressive staging, and had a higher degree of disability. However, disease-modifying therapy use was not different among courses.Competing Interest StatementAdil Javed, MD, PhD has received consultation fee or honoraria from Serono, Sanofi-Genzyme, Novartis, Biogen, Celgene and Genentech. Dr. Mirela Cerghet MD, PhD has received grants for participation in clinical trials from Merck/EMD Serono, Roche, Novartis, Biogen, and Actelion.Funding StatementThis work was not funded by any particular source.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Study was approved by each institution review board (IRB).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesDue to the sensitivity of protected health information, de-identified data will only be available upon request to corresponding author.